PMID- 22790045
OWN - NLM
STAT- MEDLINE
DCOM- 20120821
LR  - 20181201
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 39
IP  - 7
DP  - 2012 Jul
TI  - [A survey of the dosage of zoledronic acid and investigation of the relationship 
      between renal function and adverse events].
PG  - 1093-8
AB  - Zoledronic acid(ZA)dosage should be adjusted according to the risk it poses for 
      renal impairment. The recommended dosage for patients with creatinine 
      clearance(Ccr)of less than 60mL/min was established on the basis of an area under 
      the curve analysis, but is doubted because it was calculated without performing a 
      clinical trial. Creatinine secretion from the renal tubule affects Ccr; 
      therefore, using Ccr as the basis for dosage adjustment may be inappropriate 
      since this can cause an overestimation of the glomerular filtration rate(GFR). 
      The Japanese Society of Nephrology recommends using the estimated GFR(eGFR)for 
      evaluating renal function. Therefore, this study investigated the relationship 
      between renal function before and adverse events(AEs)after ZA administration. The 
      dosage of only 3 of the 47 patients with Ccr less than 60mL/min could be adjusted 
      on the basis of Ccr. During ZA therapy(3 courses), the blood urea nitrogen level 
      and occurrence of hypokalemia were higher in the non-adjusted group than in the 
      adjusted group, but the total number of AEs was equivalent for both groups. For 
      all the patients, Ccr and eGFR were used as parameters for investigating AEs; the 
      total number of AEs was equivalent for patients with differing levels of renal 
      function. Therefore, we suggest that AEs observed during ZA therapy did not 
      depend on the renal function level before ZA administration.
FAU - Yanae, Masashi
AU  - Yanae M
AD  - Dept. of Pharmacy, Sakai Hospital, Kinki University Faculty of Medicine, Japan.
FAU - Nakao, Mariko
AU  - Nakao M
FAU - Fujiwara, Kimiko
AU  - Fujiwara K
FAU - Kawaguchi, Akinori
AU  - Kawaguchi A
FAU - Tsubaki, Masanobu
AU  - Tsubaki M
FAU - Chiba, Yasutaka
AU  - Chiba Y
FAU - Morita, Tetsuya
AU  - Morita T
FAU - Yamazoe, Yuzuru
AU  - Yamazoe Y
FAU - Nishida, Shozo
AU  - Nishida S
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Imidazoles)
RN  - 6XC1PAD3KF (Zoledronic Acid)
RN  - MU72812GK0 (Creatine)
SB  - IM
MH  - Aged
MH  - Bone Density Conservation Agents/*adverse effects/therapeutic use
MH  - Bone Neoplasms/drug therapy/secondary
MH  - Creatine/blood
MH  - Diphosphonates/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Imidazoles/*adverse effects/therapeutic use
MH  - Kidney/*drug effects/*physiology
MH  - Male
MH  - Middle Aged
MH  - Zoledronic Acid
EDAT- 2012/07/14 06:00
MHDA- 2012/08/22 06:00
CRDT- 2012/07/14 06:00
PHST- 2012/07/14 06:00 [entrez]
PHST- 2012/07/14 06:00 [pubmed]
PHST- 2012/08/22 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2012 Jul;39(7):1093-8.